ArticleCureus2024
Iron Overload in Histidine-to-Aspartic Acid Substitution at 63 (H63D) Gene Heterozygous Hereditary Hemochromatosis With Erythrocytosis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Contribution of HFE H63D Mutation to Secondary Polycythemia Pathogenesis at Moderate-High Altitude: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary hemochromatosis occurs due to genetic mutations, namely, cysteine-to-tyrosine substitution at amino acid 282 (C282Y) and histidine-to-aspartic acid substitution at 63 (H63D) mutations. The role of H63D mutation in hemochromatosis is less clear, and its penetrance is low even in homozygotes. Therefore, iron overload in H63D heterozygotes is extremely rare and scarcely reported. We report the case of an asymptomatic Sinhalese man, previously unscreened, who was found to have elevated liver enzymes and hemoglobin in a routine medical check-up. His ferritin was 1272 (ng/ml) (22-322) with a transferrin saturation of 61% (15-50%). MRI of the abdomen for iron content revealed primary early iron deposition in the liver and pancreas with sparing of the spleen. Genetic studies detected H63D heterozygous homeostatic iron regulator (HFE) gene mutation with a normal C282Y gene. In his erythrocytosis workup, his erythropoietin level was suppressed. However, bone marrow biopsy did not reveal morphology suggestive of a clonal disorder, and he was negative for JAK2 V617F mutation, MPL gene, JAK2 exon 12 mutations, and calreticulin gene. He was diagnosed with H63D heterozygous hereditary hemochromatosis with iron overload and erythrocytosis and commenced on venesections as treatment for both conditions, with a good response. This case report highlights the rare possibility of developing clinically significant iron overload in H63D heterozygous hereditary hemochromatosis. Furthermore, several studies have reported the detection of HFE mutations in patients previously diagnosed with 'idiopathic' erythrocytosis. Hence, this case report calls attention to the need to suspect the presence of HFE gene mutations in patients with erythrocytosis with a negative workup for clonal red cell disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.